A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine protects vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine functions by stimulating the mother’s body’s defences to generate defence proteins, which are then transferred to the developing baby through the placenta. This mother-derived protection offers newborns with immediate protection from the moment of birth, precisely when they are highly susceptible to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence suggesting that a two-week gap is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when immunised four weeks before birth
- Antibodies from the mother transferred through placenta protect newborns from day one
- Coverage achievable with 2-week gap before early delivery
- Vaccination during the third trimester still provides significant infant protection
Strong evidence from recent research
The performance of the pregnancy RSV vaccine has been established through a extensive research programme carried out throughout England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90 per cent of all births during that half-year window, providing robust and representative information of the vaccine’s actual performance. The study’s results have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The breadth of this investigation gives healthcare professionals and expectant parents with confidence in the vaccine’s established performance across diverse populations and circumstances.
The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV during the study period, with the great majority being infants whose mothers had not received the vaccination. This marked difference emphasises the vaccine’s essential role in reducing the risk of serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a substantial public health milestone, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospitalisations. The large sample size and thorough nature of the data gathering ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology assessed real-world outcomes rather than laboratory-based settings, providing real-world data of how the vaccine functions when administered across different clinical contexts and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and its risks
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection triggers deep inflammation in the lungs and airways, making it perilously hard for affected infants to feed and breathe effectively. Parents frequently observe their babies struggling visibly, their chests rising whilst they attempt to draw enough air into their weakened respiratory system. Whilst the majority of babies get better with clinical support, a modest yet notable group succumb from RSV complications yearly, making immunisation programmes a essential public health imperative for defending the youngest and most vulnerable members of society.
- RSV causes lung inflammation, causing serious respiratory problems in babies
- Nearly 50% of infants contract the infection in their first few months of life
- Symptoms range from mild colds to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK infants need serious hospital treatment for RSV each year
- Small numbers of babies succumb to RSV related complications annually in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme commenced in 2024, health officials have emphasised the significance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns benefit from the strongest possible immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts encourage women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to increase the antibodies passed to their babies via the placenta.
The messaging from public health bodies remains clear: pregnant women should make a priority of getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of serious illness.
Regional variations in vaccination
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Certain regions have attained higher vaccination coverage among eligible pregnant women, whilst others continue working to increase awareness and availability of the jab. These geographical variations demonstrate variations in medical facilities, communication strategies, and community involvement initiatives, though the overall statistics shows robust and reliable protection regardless of geographical location.
- NHS trusts deploying diverse outreach initiatives to engage with expectant mothers
- Regional disparities in immunisation take-up across England demand focused enhancement
- Community health services modifying schemes to meet community needs and circumstances
Practical implications and parental perspectives
The vaccine’s remarkable effectiveness translates into tangible benefits for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the introduction of this protective measure, the 80% decrease in admissions equates to thousands of infants spared from severe infection. Parents no longer face the upsetting situation of watching their newborns struggle for breath or difficulty feeding, symptoms that define critical RSV illness. The vaccine has fundamentally shifted the terrain of neonatal lung health, giving expectant mothers a preventative option to shield their youngest infants during those critical early months.
For families like that of Malachi, whose acute RSV infection resulted in devastating brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s advocacy for the jab underscores the life-altering consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to women in pregnancy during their late pregnancy, changing what was once an unavoidable seasonal threat into a manageable health risk.